OBJECTIVE: Utilizing data obtained during a multicenter investigation, this paper illustrates how the use of covariates and careful modeling techniques can be useful in assessing whether a negative outcome from a small multicenter clinical trial could be due to imbalance in baseline characteristics. The Chemoprevention for Barrett's Esophagus Trial (CBET) was a phase IIb, multicenter, randomized, placebo-controlled trial of celecoxib in patients with Barrett's esophagus. The primary outcomes for the original study were the proportion of biopsy samples exhibiting dysplasia in the celecoxib and placebo groups. The secondary and tertiary outcomes included histologic change and measurements of biologically relevant markers, including COX-1 and -2 mRNA, prostanoid levels, and methylation of tumor suppressor genes p16, APC, and E-cadherin. The original study reported no significant differences in primary, secondary or tertiary outcomes. In this paper, we focus on the results of one of the secondary measures, quantitative endoscopy (QE). DESIGN: The study utilizes data from 56 patients in the CBET for whom baseline (BL) QE and one-year follow-up QE (F04) studies were performed. Of these, 29 were treated with celecoxib (200 mg twice daily for a minimum of 48 weeks) and 27 received the placebo. These patients are segmented as to the presence or absence of circumferential, tongues or islands of Barrett's. MEASUREMENTS: The response of interest is total affected area at one year (Total F04); affected area at baseline (Total BL) is used as a covariate. RESULTS: Controlling for complexity and clinic, there is a significant treatment effect. In addition, there is significant evidence that the area of Barrett's involvement decreased for patients in the treatment group. CONCLUSIONS: That there was a decrease for the celecoxib over the placebo group adds to the body of evidence that relates COX-2 specific inhibitors and cancer incidence.
RCT Entities:
OBJECTIVE: Utilizing data obtained during a multicenter investigation, this paper illustrates how the use of covariates and careful modeling techniques can be useful in assessing whether a negative outcome from a small multicenter clinical trial could be due to imbalance in baseline characteristics. The Chemoprevention for Barrett's Esophagus Trial (CBET) was a phase IIb, multicenter, randomized, placebo-controlled trial of celecoxib in patients with Barrett's esophagus. The primary outcomes for the original study were the proportion of biopsy samples exhibiting dysplasia in the celecoxib and placebo groups. The secondary and tertiary outcomes included histologic change and measurements of biologically relevant markers, including COX-1 and -2 mRNA, prostanoid levels, and methylation of tumor suppressor genes p16, APC, and E-cadherin. The original study reported no significant differences in primary, secondary or tertiary outcomes. In this paper, we focus on the results of one of the secondary measures, quantitative endoscopy (QE). DESIGN: The study utilizes data from 56 patients in the CBET for whom baseline (BL) QE and one-year follow-up QE (F04) studies were performed. Of these, 29 were treated with celecoxib (200 mg twice daily for a minimum of 48 weeks) and 27 received the placebo. These patients are segmented as to the presence or absence of circumferential, tongues or islands of Barrett's. MEASUREMENTS: The response of interest is total affected area at one year (Total F04); affected area at baseline (Total BL) is used as a covariate. RESULTS: Controlling for complexity and clinic, there is a significant treatment effect. In addition, there is significant evidence that the area of Barrett's involvement decreased for patients in the treatment group. CONCLUSIONS: That there was a decrease for the celecoxib over the placebo group adds to the body of evidence that relates COX-2 specific inhibitors and cancer incidence.
Authors: Linetta B Koppert; Bas P L Wijnhoven; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens Journal: J Surg Oncol Date: 2005-12-01 Impact factor: 3.454
Authors: Elisabeth I Heath; Marcia Irene Canto; Steven Piantadosi; Elizabeth Montgomery; Wilfred M Weinstein; James G Herman; Andrew J Dannenberg; Vincent W Yang; Albert O Shar; Ernest Hawk; Arlene A Forastiere Journal: J Natl Cancer Inst Date: 2007-04-04 Impact factor: 13.506
Authors: R Kim; B B Baggott; S Rose; A O Shar; D L Mallory; S S Lasky; M Kressloff; L Y Faccenda; J C Reynolds Journal: Gastroenterology Date: 1995-02 Impact factor: 22.682
Authors: L M Brown; D T Silverman; L M Pottern; J B Schoenberg; R S Greenberg; G M Swanson; J M Liff; A G Schwartz; R B Hayes; W J Blot Journal: Cancer Causes Control Date: 1994-07 Impact factor: 2.506
Authors: A O Shar; Marie A Gaudard; Elisabeth I Heath; Arlene A Forastiere; Vincent W Yang; Stephen J Sontag Journal: Dis Esophagus Date: 2008-06-02 Impact factor: 3.429
Authors: Martin Wagner; Benjamin Friedrich Berthold Mayer; Sebastian Bodenstedt; Katherine Stemmer; Arash Fereydooni; Stefanie Speidel; Rüdiger Dillmann; Felix Nickel; Lars Fischer; Hannes Götz Kenngott Journal: Surg Endosc Date: 2018-03-05 Impact factor: 4.584
Authors: Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk Journal: CA Cancer J Clin Date: 2015-08-18 Impact factor: 508.702
Authors: Martin Scheer; Uta Drebber; Kai Breuhahn; Christoph Möckel; Tobias Reuther; Michael Kern; Joachim E Zöller Journal: Oral Maxillofac Surg Date: 2010-03